Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.

Drug induced liver injury (DILI) presents a significant challenge for the pharmaceutical industry and regulatory authorities during preclinical and clinical phases, and in the post-marketing stage of a drug’s life cycle. Using animal and 2D models to predict human DILI has known issues as they lack full physiological relevance. The need for better predictive drug development tools is obvious, particularly in light of the rapid growth of, and increasing interest in advanced new therapeutic modalities.

In this webinar, Dr. Anna Borgström (Senior Scientist, Liver Safety, InSphero) presents the latest advancements in the hepatic safety assessment of drugs using human 3D liver spheroids – stable primary cell-based systems that accurately model the human liver in vitro. In the second part of the session, Dr. Frauke Greve (Senior Product Manager, Cell-culture technologies, InSphero) addresses the key technologies that brought the DILI model to industry application – backing up biological relevance with reproducible and scalable 3D cell culture systems.

Key Topics Include:

  • How 2D cell cultures compare with human-derived 3D cell cultures to predict hepatotoxicity and human DILI
  • Advantages and physiological relevance of human-derived liver spheroids
  • How to integrate a biologically relevant 3D model in an automated and reproducible workflow

Presenters

Senior Scientist
Liver Safety
InSphero

Dr. Anna Borgström is a cell and molecular biologist by training, with over 10 years of experience, working on a variety of scientific topics and sharpening her skills in cell biology, cell-based assays, and diagnostic assay development. In early 2022 she joined InSphero as Senior Scientist, leading the customer-based service studies, providing solutions for liver safety inquiries, and establishing 3D models as an alternative to in vivo testing. In her role Anna supports the development of high-throughput compatible assays and is working towards the development of next-generation testing methods for drug toxicity. Dr. Borgström earned her PhD at the University of Zurich in 2013.

Senior Product Manager
Cell-Culture Technologies
InSphero

Dr. Frauke Greve is an experienced technology professional combing technical skills, analytical thinking, and perseverance. She joined InSphero in 2015 as part of the Technology and Platforms team. In her role as a Senior Product Manager for the Cell-culture consumables Dr. Greve works closely with researchers to develop new technologies for 3D cell handling and the various, specially designed ultra-low attachment Akura™ Spheroid Microplate Solutions. Frauke studied Electrical Engineering at the Federal Institute of Technology (ETH) and completed her PhD in Microelectronics in 2006.

Production Partner

InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of 3D InSight™ Platforms and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreatic islet, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized format, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and on-site training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models. InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with a US subsidiary in Brunswick, ME. It has been recognized for its scientific and commercial achievements with several national and international awards. In addition, InSphero has implemented and maintains a quality management system that has been verified to fulfill the requirements of the ISO 9001:2015 standard.

Related Content